New/emerging psychoactive substances and associated psychopathological consequences
Open accessThe DOI matches its Crossref record; 125 of the 126 references it cites were found in a registry or an index.
Abstract
Background: The present paper provides an updated review of both the large number of new/novel/emerging psychoactive substances (NPS) and their associated psychopathological consequences. Focus was here given on identification of those NPS being commented in specialised online sources and the related short-/long-term psychopathological and medical ill-health effects. Methods: NPS have been identified through an innovative crawling/navigating software, called the ‘NPS.Finder®’, created in order to facilitate the process of early recognition of NPS online. A range of information regarding NPS, including chemical and street names; chemical formula; three-dimensional image and anecdotally reported clinical/psychoactive effects, were here made available. Results: Using the ‘NPS.Finder®’ approach, a few thousand NPS were here preliminarily identified, a number which is about 4-fold higher than those figures suggested by European and international drug agencies. NPS most commonly associated with the onset of psychopathological consequences included here synthetic cannabinoids/cannabimimetics; new synthetic opioids; ketamine-like dissociatives; novel stimulants; novel psychedelics and several prescription and over-the-counter medicines. Conclusions: The ever-increasing changes in terms of recreational psychotropics' availability represent a relatively new challenge for psychiatry, as the pharmacodynamics and pharmacokinetics of many NPS have not been thoroughly understood. Health/mental health professionals should be informed about the range of NPS; their intake modalities; their psychoactive sought-after effects; the idiosyncratic psychotropics' combinations and finally, their medical and psychopathological risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Indeed, when tapering down a therapeutic dosage AD, symptoms most typically are both mild/go untreated; and resolve spontaneously (21).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liking, wanting, and the incentive-sensitization theory of addiction
Berridge, K. C., & Robinson, T. E. (2016) · American Psychologist · doi:10.1037/amp0000059 · Cited by 1,440
Handbook of experimental pharmacology
(1984) · International Journal of Biochemistry · doi:10.1016/0020-711x(84)90023-5 · Cited by 1,417
European Monitoring Centre for Drugs and Drug Addiction
Anderson, M. (2014) · European Union regulations | European Encyclopedia of law · Cited by 1,213
Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review
Armenian, P., Vo, K. T., Barr-Walker, J., & Lynch, K. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.016 · Cited by 710
The Toxicology of Bath Salts: A Review of Synthetic Cathinones
Prosser, J. M., & Nelson, L. S. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0193-z · Cited by 705
Pharmacological characterization of designer cathinones in vitro
Simmler, L., Buser, T., Donzelli, M., Schramm, Y., Dieu, L., Huwyler, J., Chaboz, S., Hoener, M., & Liechti, M. (2013) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02145.x · Cited by 672
Hermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04078.x · Cited by 479
A review: Fentanyl and non-pharmaceutical fentanyls
Suzuki, J., & El-Haddad, S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.033 · Cited by 445
Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404 · cited 1×
“Zolpidem and zopiclone seem to be the most involved in the diversion and abuse phenomena ([ACMD], 2013), and it is likely that the misusing phenomenon is currently underestimated (Hajak et al., 2003).”
BackgroundTait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016) · Clinical Toxicology · doi:10.3109/15563650.2015.1110590 · Cited by 378
Rosenbaum, C. D., Carreiro, S. P., & Babu, K. M. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0202-2 · Cited by 355
Winstock, A. R., & Barratt, M. J. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.011 · Cited by 331
Synthetic Cannabinoid–Related Illnesses and Deaths
Trecki, J., Gerona, R. R., & Schwartz, M. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1505328 · Cited by 331
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321 · cited 10×
“There are small numbers of tryptamine-related fatalities (Schifano et al., 2015) (Table 1).”
BackgroundMethodInfluentialSelf-citationKehr, J., Ichinose, F., Yoshitake, S., Goiny, M., Sievertsson, T., Nyberg, F., & Yoshitake, T. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01499.x · Cited by 312
Spicing things up: synthetic cannabinoids
Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3188-4 · Cited by 296
Misuse of Novel Synthetic Opioids: A Deadly New Trend
Prekupec, M. P., Mansky, P. A., & Baumann, M. H. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000324 · Cited by 283
How addictive are gabapentin and pregabalin? A systematic review
Bonnet, U., & Scherbaum, N. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.430 · Cited by 281
Self-citationMephedrone: use, subjective effects and health risks: Mephedrone and health risks
Winstock, A., Mitcheson, L., Ramsey, J., Davies, S., Puchnarewicz, M., & Marsden, J. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03502.x · Cited by 273
Myocardial Infarction Associated With Use of the Synthetic Cannabinoid K2
Mir, A., Obafemi, A., Young, A., & Kane, C. (2011) · Pediatrics · doi:10.1542/peds.2010-3823 · Cited by 266
Synthetic Cathinones: A New Public Health Problem
Karila, L., Megarbane, B., Cottencin, O., & Lejoyeux, M. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666141210224137 · Cited by 245
From PCP to MXE: a comprehensive review of the non‐medical use of dissociative drugs
Morris, H., & Wallach, J. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1620 · Cited by 244
Loperamide: a pharmacological review.
Baker, D. E. (2007) · PubMed · Cited by 242
Dargan, P. I., Albert, S., & Wood, D. M. (2010) · QJM · doi:10.1093/qjmed/hcq134 · Cited by 242
Gunderson, E. W., Haughey, H. M., Ait‐Daoud, N., Joshi, A. S., & Hart, C. L. (2012) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00240.x · Cited by 226
Borek, H. A., & Holstege, C. P. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.01.005 · Cited by 223
Marinetti, L. J., & Antonides, H. M. (2013) · Journal of Analytical Toxicology · doi:10.1093/jat/bks136 · Cited by 213
Victorri‐Vigneau, C., Dailly, E., Veyrac, G., & Jolliet, P. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02861.x · Cited by 201
Wyatt, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92245-w · Cited by 197
Miliano, C., Serpelloni, G., Rimondo, C., Mereu, M., Marti, M., & De Luca, M. A. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00153 · Cited by 197
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
Self-citationPapanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., Impagnatiello, M., Pascolo‐Fabrici, E., & Bonavigo, T. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2312 · Cited by 190
Self-citationChiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189 · cited 1×
“emptying the content of the capsule into a pouch (AlHusseini et al., 2018; Chiappini and Schifano, 2016).”
BackgroundSelf-citationThe Misuse of Prescription Opioids: A Threat for Europe?
van Amsterdam, J., & van den Brink, W. (2015) · Current Drug Abuse Reviews · doi:10.2174/187447370801150611184218 · Cited by 180
An overview of recent developments in the analytical detection of new psychoactive substances (NPSs)
Smith, J. P., Sutcliffe, O. B., & Banks, C. E. (2015) · The Analyst · doi:10.1039/c5an00797f · Cited by 175
An Expanding World of Novel Psychoactive Substances: Opioids
Zawilska, J. B. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00110 · Cited by 175
Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018) · Brain Sciences · doi:10.3390/brainsci8030047 · Cited by 171
Corazza, O., Assi, S., Simonato, P., Corkery, J., Bersani, F. S., Demetrovics, Z., Stair, J., Fergus, S., Pezzolesi, C., Pasinetti, M., et al. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2299 · Cited by 168
Self-citationLegal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 159
Lethal Serotonin Syndrome After Methylone and Butylone Ingestion
Warrick, B. J., Wilson, J., Hedge, M. W., Freeman, S. B., Leonard, K., & Aaron, C. K. (2011) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0199-6 · Cited by 152
Novel psychoactive substances: types, mechanisms of action, and effects
Tracy, D. K., Wood, D. M., & Baumeister, D. (2017) · BMJ · doi:10.1136/bmj.i6848 · Cited by 151
Effects and Risks Associated with Novel Psychoactive Substances
Hohmann, N., Mikus, G., & Czock, D. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0139 · Cited by 143
Ischemic stroke after use of the synthetic marijuana “spice”
Freeman, M. J., Rose, D. Z., Myers, M. A., Gooch, C. L., Bozeman, A. C., & Burgin, W. S. (2013) · Neurology · doi:10.1212/01.wnl.0000437297.05570.a2 · Cited by 138
Designer drugs 2015: assessment and management
Weaver, M. F., Hopper, J. A., & Gunderson, E. W. (2015) · Addiction Science & Clinical Practice · doi:10.1186/s13722-015-0024-7 · Cited by 134
Synthetic cannabinoid withdrawal: A new demand on detoxification services
Macfarlane, V. F. H., & Christie, G. (2015) · Drug and Alcohol Review · doi:10.1111/dar.12225 · Cited by 127
Karila, L., Billieux, J., Benyamina, A., Lançon, C., & Cottencin, O. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.005 · Cited by 125
‘I can't be an addict. I am.’ Over-the-counter medicine abuse: a qualitative study
Cooper, R. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002913 · Cited by 118
Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’
Freeman, T. P., Morgan, C. J. A., Vaughn‐Jones, J., Hussain, N., Karimi, K., & Curran, H. V. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03719.x · Cited by 116
Detection of JWH-018 and JWH-073 by UPLC-MS-MS in Postmortem Whole Blood Casework
Shanks, K. G., Dahn, T., & Terrell, A. R. (2012) · Journal of Analytical Toxicology · doi:10.1093/jat/bks013 · Cited by 116
Characteristics of deaths associated with kratom use
Corkery, J., Streete, P., Claridge, H., Goodair, C., Papanti, D., Orsolini, L., Schifano, F., Sikka, K., Körber, S., & Hendricks, A. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119862530 · Cited by 109
Self-citationDesigner benzodiazepines: A new challenge
Moosmann, B., King, L. A., & Auwärter, V. (2015) · World Psychiatry · doi:10.1002/wps.20236 · Cited by 108
A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids
Hopkins, C. Y., & Gilchrist, B. L. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2012.11.034 · Cited by 107
Simonato, P., Corazza, O., Santonastaso, P., Corkery, J., Deluca, P., Davey, Z., Blaszko, U., & Schifano, F. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2300 · Cited by 106
Self-citationDeath following ingestion of methylone
Barrios, L., Grison-Hernando, H., Boels, D., Bouquié, R., Monteil‐Ganière, C., & Clément, R. (2015) · International Journal of Legal Medicine · doi:10.1007/s00414-015-1212-4 · Cited by 104
New psychoactive substances of natural origin: A brief review
Feng, L., Battulga, A., Han, E., Chung, H., & Li, J. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.04.001 · Cited by 101
Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA
Angerer, V., Jacobi, S., Franz, F., Auwärter, V., & Pietsch, J. (2017) · Forensic Science International · doi:10.1016/j.forsciint.2017.10.042 · Cited by 100
K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure
Patton, A. L., Chimalakonda, K. C., Moran, C. L., McCain, K. R., Radominska‐Pandya, A., James, L. P., Kokes, C., & Moran, J. H. (2013) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12216 · Cited by 96
Hallucinatory delirium following use of MDPV: “Bath Salts”
Penders, T. M., & Gestring, R. E. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.05.014 · Cited by 93
Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018) · Brain Sciences · doi:10.3390/brainsci8040073 · Cited by 93
Self-citationMisuse of benzodiazepines and Z-drugs in the UK
Kapil, V., Green, J. L., Lait, C. L., Wood, D. M., & Dargan, P. I. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.149252 · Cited by 92
Abuse and misuse of antidepressants
Sullivan, M., & Evans, E. (2014) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s37917 · Cited by 91
Mind Navigators of Chemicals' Experimenters? A Web-Based Description of E-Psychonauts
Orsolini, L., Papanti, G. D., Francesconi, G., & Schifano, F. (2015) · Cyberpsychology, Behavior, and Social Networking · doi:10.1089/cyber.2014.0486 · Cited by 89
Self-citationExcited Delirium, Restraints, and Unexpected Death
Otahbachi, M., Çevik, C., Bagdure, S., & NUGENT, K. M. (2010) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0b013e3181d76cdd · Cited by 86
Abuse of over-the-counter medicines: a pharmacist’s perspective
Sansgiry, S. S., Bhansali, A. H., Bapat, S., & Xu, Q. (2016) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s103494 · Cited by 84
Wood, D. M., & Dargan, P. I. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31825b954b · Cited by 83
Winstock, A. R., & Barratt, M. J. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2292 · Cited by 83
Excited delirium following use of synthetic cathinones (bath salts)
Penders, T. M., Gestring, R. E., & Vilensky, D. A. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.06.005 · Cited by 82
Recurrent Acute Kidney Injury Following Bath Salts Intoxication
Adebamiro, A., & Perazella, M. A. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.10.012 · Cited by 81
Newly Emerging Drugs of Abuse and Their Detection Methods
Liu, L., Wheeler, S., Venkataramanan, R., Rymer, J. A., Pizon, A. F., Lynch, M. J., & Tamama, K. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqx138 · Cited by 78
Dextromethorphan abuse: Clinical effects and management
Romanelli, F., & Smith, K. M. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.08091 · Cited by 77 · cited 1×
“Psychotropic effects include trance-like euphoria/stupor, hyper excitability, depersonalisation, dyskinesia, delayed response times, disordered speech and vivid auditory/visual hallucinations (Romanelli and Smith, 2009).”
BackgroundSynthetic Cannabis-Induced Mania
Üstündağ, M. F., İbiş, E., Yücel, A., & Özcan, H. (2015) · Case Reports in Psychiatry · doi:10.1155/2015/310930 · Cited by 76
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., Lodge, D., Halberstadt, A. L., Brandt, S. D., & Adejare, A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157021 · Cited by 76
Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids
Solimini, R., Pichini, S., Pacifici, R., Busardò, F. P., & Giorgetti, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00654 · Cited by 75
Capriola, M. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s42832 · Cited by 74
Fatalities caused by novel opioids: a review
Drummer, O. H. (2019) · Forensic Sciences Research · doi:10.1080/20961790.2018.1460063 · Cited by 73
Serotonin Syndrome Associated With MDPV Use: A Case Report
Mugele, J., Nañagas, K., & Tormoehlen, L. M. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.11.033 · Cited by 72
Marchei, E., Pacifici, R., Mannocchi, G., Marinelli, E., Busardò, F. P., & Pichini, S. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.01.007 · Cited by 70
Boyer, E. W., Fletcher, R., Fay, R. J., Smelson, D. A., Ziedonis, D. M., & Picard, R. W. (2012) · Journal of Medical Toxicology · doi:10.1007/s13181-011-0200-4 · Cited by 69
Mdege, N. D., Meader, N., Lloyd, C., Parrott, S., & McCambridge, J. (2017) · Public Health Research · doi:10.3310/phr05040 · Cited by 69
Novel psychoactive substances: the pharmacology of stimulants and hallucinogens
Schifano, F., Papanti, G. D., Orsolini, L., & Corkery, J. M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1167597 · Cited by 67
Self-citationNPS: Medical Consequences Associated with Their Intake
Schifano, F., Orsolini, L., Papanti, D., & Corkery, J. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_15 · Cited by 67
Self-citationNovel Synthetic Opioids: An Opioid Epidemic Within an Opioid Epidemic
Lucyk, S. N., & Nelson, L. S. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.08.445 · Cited by 62
ON THE ADDICTIVE POWER OF GABAPENTINOIDS: A MINI-REVIEW
Bonnet, U., Richter, E.-L., Isbruch, K., & Scherbaum, N. (2018) · Psychiatria Danubina · doi:10.24869/psyd.2018.142 · Cited by 60
Self-citationHemorrhagic stroke following use of the synthetic marijuana “spice”
Rose, D. Z., Guerrero, W. R., Mokin, M. V., Gooch, C. L., Bozeman, A. C., Pearson, J. M., & Burgin, W. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001973 · Cited by 57
New and Emerging Illicit Psychoactive Substances
Graddy, R., Buresh, M., & Rastegar, D. A. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.010 · Cited by 57
Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000–2010
Wilson, M. D., Ferguson, R. W., Mazer, M. E., & Litovitz, T. L. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.585429 · Cited by 56
Use of Synthetic Cannabinoids in Patients With Psychotic Disorders: Case Series
Celofiga, A., Koprivsek, J., & Klavz, J. (2014) · Journal of Dual Diagnosis · doi:10.1080/15504263.2014.929364 · Cited by 54
Shafi, A., Gallagher, P., Stewart, N., Martinotti, G., & Corazza, O. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2606 · Cited by 53
Synthetic Cannabinoid-Induced Psychosis: Two Adolescent Cases
Oluwabusi, O. O., Lobach, L., Akhtar, U., Youngman, B., & Ambrosini, P. J. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0004 · Cited by 52
Teens and Spice: A Review of Adolescent Fatalities Associated with Synthetic Cannabinoid Use
Paul, A. B. M., Simms, L., Amini, S., & Paul, A. E. (2018) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13704 · Cited by 51
Ventura, L. G. M., Carvalho, F. D., & Dinis‐Oliveira, R. J. (2017) · Current Molecular Pharmacology · doi:10.2174/1874467210666170704110146 · Cited by 50
Bonaccorso, S., Metastasio, A., Ricciardi, A., Stewart, N., Jamal, L., Rujully, N.-U.-D., Theleritis, C. G., Ferracuti, S., Ducci, G., & Schifano, F. (2018) · Brain Sciences · doi:10.3390/brainsci8070133 · Cited by 50
Self-citation1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances
Wallach, J. V., & Brandt, S. D. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_148 · Cited by 50
Chiappini, S., & Schifano, F. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000814 · Cited by 44
Self-citationSchifano, F., & Chiappini, S. (2018) · PLOS ONE · doi:10.1371/journal.pone.0204443 · Cited by 44 · cited 2×
“Cytochrome inhibitors, such as cimetidine, omeprazole and grapefruit juice, as well as P-glycoprotein inhibitors, such as quinidine-quinine and pepper, may be concomitantly used to raise the drug blood levels (Baker, 2007; Schifano and Chiappini, 2018b) (Table 1).”
BackgroundSelf-citationHomman, L. E., Seglert, J., & Morgan, M. J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4953-1 · Cited by 43
Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics
Klein, L., Bangh, S., & Cole, J. (2017) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2016.10.32322 · Cited by 42
Hospitalisation associated with use of the synthetic cannabinoid K2.
Glue, P., Al‐Shaqsi, S., Hancock, D., Gale, C. K., Strong, B., & Schep, L. J. (2013) · PubMed · Cited by 39
Anticoagulation clinic workflow analysis
Romanelli, F., & Smith, K. M. (2009) · Journal of the American Pharmacists Association · Cited by 39
Increasing rates of quetiapine overdose, misuse, and mortality in Victoria, Australia
Lee, J., Schumann, J., Gerostamoulos, D., Robinson, J., & Wong, A. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.03.002 · Cited by 39
Vårdal, L., Wong, G., Øiestad, Å. M. L., Pedersen‐Bjergaard, S., Gjelstad, A., & Øiestad, E. L. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1147-y · Cited by 39
Is There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38
Self-citationA 'spicy' encephalopathy: synthetic cannabinoids as cause of encephalopathy and seizure
Louh, I. K., & Freeman, W. D. (2014) · Critical Care · doi:10.1186/s13054-014-0553-6 · Cited by 36
Corkery, J., Orsolini, L., Papanti, D., & Schifano, F. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2566 · Cited by 36
Self-citationBath Salts Intoxication: A Case Series
Imam, S., Patel, H., Mahmoud, M., Prakash, N. A., King, M. S., & Fremont, R. D. (2013) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2013.04.017 · Cited by 35
Bath Salts Abuse Leading to New-Onset Psychosis and Potential for Violence
John, M. E., Thomas-Rozea, C., & Hahn, D. R. (2014) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.joro.061314 · Cited by 28
Neurocognitive performance following acute mephedrone administration, with and without alcohol
Perna, E. B. D. S. F., Papaseit, E., Pérez‐Mañá, C., Mateus, J., Theunissen, E. L., Kuypers, K. P. C., de la Torre, R., Farré, M., & Ramaekers, J. G. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116662635 · Cited by 28
Martinotti, G., Cinosi, E., Santacroce, R., Papanti, D., Pasquini, A., Mancini, V., Corbo, M., Fiori, F., Sarchione, F., Marchetti, D., et al. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2586 · Cited by 28
Self-citationLee, V. R., Vera, A., Alexander, A. B., Ruck, B. E., Nelson, L. S., Wax, P. M., Campleman, S. L., Brent, J. A., & Calello, D. P. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1510128 · Cited by 28
Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse
Vento (2013) · PubMed · doi:10.4415/ann_13_04_14 · Cited by 26
Self-citationHerzig, D. A., Brooks, R., & Möhr, C. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2307 · Cited by 25
Products containing synthetic cannabinoids and psychosis
Brakoulias, V. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867411433974 · Cited by 25
Francesconi, G., Orsolini, L., Papanti, D., Corkery, J. M., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2476 · Cited by 22
Self-citationAB-CHMINACA-induced sudden death from non-cardiogenic pulmonary edema
Maeda, H., Kikura‐Hanajiri, R., Kawamura, M., Nagashima, E., & Yoshida, K. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1340648 · Cited by 20
Corkery, J., Orsolini, L., Papanti, D., & Schifano, F. (2018) · Comprehensive series in photochemistry and photobiology/Comprehensive series in photochemical & photobiological sciences · doi:10.1039/9781788010344-00207 · Cited by 18
Self-citation“Robo-Tripping”: Dextromethorphan Abuse and its Anesthetic Implications
Linn, K. A., Long, M. T., & Pagel, P. S. (2014) · Anesthesiology and Pain Medicine · doi:10.5812/aapm.20990 · Cited by 17
Abuse of Tricyclic Antidepressant Drugs: A Case Series
Shenouda, R., & Desan, P. H. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182901142 · Cited by 17
Guide to the management of gabapentinoid misuse
Parsons, G. (2018) · Prescriber · doi:10.1002/psb.1664 · Cited by 16
An adolescent with an altered state of mind
Naviglio, S., Papanti, D., Moressa, V., & Ventura, A. (2015) · BMJ · doi:10.1136/bmj.h299 · Cited by 12
Pregabalin Misuse and Abuse: A Scoping Review of Extant Literature
Al-Husseini, A., Hout, M. C. V., & Wazaify, M. (2018) · Journal of Drug Issues · doi:10.1177/0022042618759487 · Cited by 12
Synthetic Cathinones and Related Fatalities in the United Kingdom
Corkery, J., Goodair, C., & Claridge, H. (2018) · Routledge eBooks · doi:10.4324/9781315158082-11 · Cited by 9
Self-citationGhodse, H., Corkery, J., Ahmed, K., Naidoo, V., Oyefeso, A. O., & Schifano, F. (2010) · Cited by 7
Self-citationSynthetic Cannabinoid Effects on Behavior and Motivation
Wessinger, W. D., Moran, J. H., & Seely, K. A. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2294-9_9 · Cited by 6
Kaizer-Będkowska, M. J., & Kucia, K. A. (2018) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2018.0018 · Cited by 4
The case of the Norwegian teen who died from synthetic cannabinoids
Olsen, J. F. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518798439 · Cited by 1
Research works printed but not linked: 12
- UNODC (2018). Analysis of drug markets: opiates, cocaine, cannabis, synthetic drugs. Vienna: UNODC. Available from: http://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_3_DRUG_MARKET S.pdf (accessed on October 21,2018).
- Lovrecic, B. and Lovrecic, M. (2017). Novel psychoactive synthetic cannabinoids and synthetic cathinones: the never-ending story of potential clinical toxicity. Heroin Addiction and Related Clinical Problems. Available from: https://www.researchgate.net/profile/Barbara_Lovrecic/publication/319554544
- Cheng, S., Yeo, J., Brown, E., Regan, A. (2012). Bath Salts and Synthetic Cannabinoids: A Review. American Academy of Emergency Medicine 19, 19-22.
- UNODC (2018). World Drug Report 2018 Volume 3 -Analysis of drug markets: opiates, cocaine, cannabis, synthetic drugs. Vienna: United Nations Office on Drugs and Crime. Available from: https://www.unodc.org/wdr2018/ (accessed on November 23, 2018).
- UNODC (2013). The challenge of new psychoactive substances: A Report from the Global SMART Programme. Vienna: United Nations Office on Drugs and Crime. Available from: https://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf (accessed on November 23, 2018).
- Denysenko, L., Freudenreich, O., Philbrick, K., Penders, T., Zimbrean, P., Nejad, S., Chwastiak, L., Dickerman, A., Niazi, S., Shim, J., Soellner, W. (2015). Catatonia in Medically Ill Patients An Evidence-Based Medicine (EBM) Monograph for Psychosomatic Medicine Practice. The European Association of Psychosomatic Medicine 30, 140-155.
- Chatwin, C., Measham, F., O'Brien, K., Sumnall, H. (2017). New Psychoactive Substances and Human Enhancement Drugs. International Journal of Drug Policy 40, 1-5.
- Brennan, B.P., Kanayama, G., Pope, H.G. Jr (2013). Performance-enhancing drugs on the web: a growing public-health issue. The American Journal of Addiction 22, 158-61.
- Brennan, R., Wells, J.S.G., Van Hout, M.C. (2017). The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review. Health and Social Care in the Community 25, 1459-1531.
- Callaghan Iii, D.J. (2018). A glimpse into the underground market of melanotan. Dermatology Online Journal 24(5). pii: 13030/qt2gz9f9jk.
- Santos, G.H. and Coomber, R. (2017). The risk environment of anabolic- androgenic steroid users in the UK: Examining motivations, practices and accounts of use. International Journal of Drug Policy Volume 40, 35-43.
- 2017, High Risk Drug use and New Psychoactive Substances. EMCDDA Rapid Communication
Cited by
The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review
Sharif, S., Guirguis, A., Fergus, S., & Schifano, F. (2021) · Brain Sciences · doi:10.3390/brainsci11030355 · Cited by 166
Self-citationAn updated review on synthetic cathinones
Soares, J., Costa, V. M., Bastos, M. D. L., Carvalho, F. D., & Capela, J. P. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03083-3 · Cited by 136
Substance-related exogenous psychosis: a postmodern syndrome
Martinotti, G., Risio, L. D., Vannini, C., Schifano, F., Pettorruso, M., & Giannantonio, M. D. (2020) · CNS Spectrums · doi:10.1017/s1092852920001479 · Cited by 111
Self-citationNew Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature
Chiappini, S., Mosca, A., Miuli, A., Santovito, M. C., Orsolini, L., Corkery, J., Guirguis, A., Pettorruso, M., Martinotti, G., Giannantonio, M. D., et al. (2021) · Medicina · doi:10.3390/medicina57060580 · Cited by 105
Self-citationSynthetic Cathinones and Neurotoxicity Risks: A Systematic Review
Daziani, G., Faro, A. F. L., Montana, V., Goteri, G., Pesaresi, M., Bambagiotti, G., Montanari, E., Giorgetti, R., & Montana, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076230 · Cited by 80
Metadata
- Authors
- Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A.
- Affiliations
- University of Hertfordshire (GB)
- Homerton University Hospital (GB)
- Swansea University (GB)
- Camden and Islington NHS Foundation Trust (GB)
- ASL Roma (IT)
- University of Duisburg-Essen (DE)
- Marconi University (IT)
- Corresponding author
- Chiappini, S.
- ORCID
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2019-07-22
- Volume
- 51
- Issue
- 1
- Pages
- 30-42
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2957505335
- Cited by
- 119
- References
- 126
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 18 · 2023: 14 · 2022: 15 · 2021: 22 · 2020: 14 · 2019: 4
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-07-22)
- Open access
- green
- hdl.handle.net
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (acceptedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- new psychoactive substances, synthetic cannabinoids, synthetic opioids, prescription drug misuse, psychopathological consequences, recreational drug use, mental health risk
- MeSH terms
- Recreational Drug Use, Humans, Psychopathology, Psychotropic Drugs, Illicit Drugs, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.